Tobira Therapeutics Inc. (NASDAQ:TBRA) rose 3.2% during trading on Thursday . The company traded as high as $4.82 and last traded at $4.77, with a volume of 136,240 shares changing hands. The stock had previously closed at $4.62.

TBRA has been the topic of a number of recent analyst reports. Zacks Investment Research cut shares of Tobira Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, April 22nd. Leerink Swann reiterated a “buy” rating on shares of Tobira Therapeutics in a report on Monday, May 2nd. HC Wainwright reiterated a “buy” rating on shares of Tobira Therapeutics in a report on Wednesday, May 4th. Cowen and Company reiterated a “buy” rating on shares of Tobira Therapeutics in a report on Tuesday, May 10th. Finally, Cantor Fitzgerald began coverage on shares of Tobira Therapeutics in a report on Wednesday, July 6th. They issued a “buy” rating and a $27.00 target price on the stock. Five investment analysts have rated the stock with a buy rating, The company has an average rating of “Buy” and a consensus target price of $16.75.

The stock has a 50 day moving average of $7.53 and a 200 day moving average of $8.30. The company’s market cap is $91.66 million.

Tobira Therapeutics (NASDAQ:TBRA) last released its quarterly earnings data on Tuesday, August 9th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.63) by $0.08. The business had revenue of $1.06 million for the quarter. On average, equities analysts expect that Tobira Therapeutics Inc. will post ($2.65) EPS for the current fiscal year.

In other news, major shareholder A/S Novo sold 66,814 shares of the business’s stock in a transaction dated Thursday, June 30th. The shares were sold at an average price of $13.04, for a total value of $871,254.56. Following the completion of the sale, the insider now owns 2,073,022 shares in the company, valued at approximately $27,032,206.88. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

A hedge fund recently bought a new stake in Tobira Therapeutics stock. Marshall Wace LLP acquired a new stake in Tobira Therapeutics Inc. (NASDAQ:TBRA) during the fourth quarter, according to its most recent filing with the SEC. The institutional investor acquired 107,493 shares of the biopharmaceutical company’s stock, valued at approximately $1,080,000. Marshall Wace LLP owned about 0.57% of Tobira Therapeutics at the end of the most recent quarter.

Tobira Therapeutics, Inc, formerly Regado Biosciences, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat liver disease, inflammation, fibrosis and human immunodeficiency virus (HIV). The Company’s lead product candidate, cenicriviroc (CVC), is an immunomodulator and dual inhibitor of C-C Chemokine Receptor 2 (CCR2) and C-C Chemokine Receptor 5 (CCR5) being evaluated for the treatment of non-alcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC), and as an adjunctive therapy to standard of care in HIV.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.